Roche Holding AG (RHHBY)
| Market Cap | 257.05B |
| Revenue (ttm) | 67.42B |
| Net Income (ttm) | 11.82B |
| Shares Out | n/a |
| EPS (ttm) | 14.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 0.85 (2.11%) |
| Ex-Dividend Date | Mar 14, 2024 |
| Volume | 257,972 |
| Open | 39.79 |
| Previous Close | 39.85 |
| Day's Range | 39.65 - 40.18 |
| 52-Week Range | 29.20 - 42.43 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 18, 2024 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, d... [Read more]
Financial Performance
In 2023, Roche Holding AG's revenue was 60.44 billion, a decrease of -8.16% compared to the previous year's 65.81 billion. Earnings were 11.50 billion, a decrease of -7.43%.
Financial numbers in CHF Financial StatementsNews
Roche, Biogen kidney disease drug hits main goal in late-stage study
Positive Phase III Results for Genentech's Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis
– The REGENCY study met its primary endpoint, demonstrating statistically significant and clinically meaningful treatment benefits in people with active lupus nephritis – – Gazyva is designed to targe...
Positive phase III results for Roche's Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
Positive phase III results for Roche's Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
Positive Phase III Results for Genentech's Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase III REGENCY study of Gazyva® ...
Roche: The Devil Is In The Details - Obesity Data Presentation Disappoints
Roche narrows pipeline to 11 disease areas amidst weight loss push - WSJ
Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
Basel, 24 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the cobas® Respiratory flex test, the first to use Roche's novel and proprietary TAGS (Temperature-Activated...
WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche's role in pioneering cervical cancer solutions
Basel, 23 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the World Health Organization (WHO) has included dual-stain cytology testing in its cervical cancer prevention guidel...
Roche’s chairman says government subsidies waste money
TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval
Shares of TG Therapeutics made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS and despite Roche receiving FDA...
Roche unit hits main goal in late-stage trial for flu therapy
Roche (RHHBF) unit Genentech said Xofluza antiviral reached the main goal in a global Phase 3 trial, reducting the transmission of influzenza virus. Read more here.
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase III CENTERSTONE study of Xofluz...
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
Basel, 19 September - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results of the phase III CENTERSTONE study of Xofluza® (baloxavir marboxil), an antiviral, showing a reduction...
ESMO 2024 Roundup: A Lot Of Stumbles, But There Are New Signs Of Life
The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, Exelixis, Roche, and other biotechs.
Healthy Returns: How competitive can Roche be in the weight loss drug market?
Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health market with acquisition of Veri.
Mindpeak Announces Collaboration With Roche to Enhance Cancer Diagnostics Through AI
HAMBURG, Germany--(BUSINESS WIRE)--Mindpeak announces its collaboration with Roche that will integrate Mindpeak's innovative AI algorithm with Roche's Digital Pathology Open Environment, playing a cru...
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
Monday, the FDA approved Roche Holdings AG’s (OTC: RHHBY) Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). O...
FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) f...
Roche wins FDA approval for Ocrevus Zunovo as twice yearly multiple sclerosis therapy
FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
– Ocrevus Zunovo™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints, like at a doctor's office – – This approval is backed by a decade of proven...
FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the United States Food and Drug Administration (U.S. FDA) has ap...
AstraZeneca, Roche cut at Deutsche after trial readouts for key drugs
Roche wins FDA nod for Tecentriq version developed with Halozyme
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735
Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right track.
FDA approves Roche's Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
Basel, 13 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs), t...